Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04KYB
|
||||
| Former ID |
DIB007838
|
||||
| Drug Name |
ASCJ-9 topical
|
||||
| Synonyms |
Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience
|
||||
| Indication | Alopecia [ICD9: 704.09; ICD10:L65.9] | Phase 2 | [1] | ||
| Company |
AndroScience
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1(c(ccc(c1)/C=C/C(=O)CC(=O)/C=C/c1cc(c(cc1)OC)OC)OC)OC
|
||||
| CAS Number |
CAS 52328-98-0
|
||||
| Target and Pathway | |||||
| Target(s) | Androgen receptor | Target Info | Enhancer | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathways in cancer | |||||
| Prostate cancer | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| AndrogenReceptor Signaling Pathway | |||||
| FSH Signaling Pathway | |||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Coregulation of Androgen receptor activity | |||||
| Regulation of Androgen receptor activity | |||||
| Nongenotropic Androgen signaling | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| FOXA1 transcription factor network | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Nuclear Receptors | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01289574) Topical ASC-J9 Cream for Acne. U.S. National Institutes of Health. | ||||
| REF 2 | Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.